
Isomorphic Labs raises $5B six months after $2.1B round
London-based Isomorphic Labs has raised $5 billion (€4.5 billion) in a Series C co-led by Greenoaks and Sequoia Capital, just six months after securing $2.1 billion. The latest financing takes the Alphabet-backed AI drug developer's disclosed fundraising to $7.7 billion across three rounds since March 2025.
Why it matters: Isomorphic is attracting sums rarely seen in biotechnology, even as its internal drug pipeline remains preclinical. Its latest round alone is larger than the entire U.K. biotech sector’s venture capital investment during the first nine months of 2026.
Zoom in: Greenoaks and Sequoia co-led the round, with Andreessen Horowitz joining as a new investor. Existing backers Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund also participated.
The company did not disclose its valuation. It plans to use the capital to expand its AI drug design platform, develop new biological simulation models and build the infrastructure needed to advance its medicines into clinical development.
How it works: Isomorphic’s proprietary drug design engine, IsoDDE, combines AI models designed to predict molecular interactions and help scientists identify and optimize drug candidates across therapeutic areas and drug modalities. The company says its technology is generating positive preclinical results in its internal oncology and immunology programs, as well as through partnerships. However, the announcement provides no supporting data or details about individual drug candidates.
Backstory: Founded in 2021 as a spinout from Google DeepMind, Isomorphic has established drug discovery partnerships with Eli Lilly, Novartis and Johnson & Johnson.
When European Biotechnology ranked Isomorphic first among its 10 European startups to watch in 2026 in March, the company had raised $600 million in external funding.
Just six weeks later, it secured $2.1 billion in a Series B led by Thrive Capital. That financing accounted for roughly three-quarters of all U.K. biotech venture capital investment in the second quarter, pushing the sector’s funding to a five-year high.
The bigger picture: The BioIndustry Association’s latest figures show that U.K. biotech companies raised £2.8 billion (about €3.4 billion) in venture capital during the first nine months of 2026. The new Isomorphic round alone is worth approximately £3.8 billion.
The association has warned that the sector’s headline funding figures are increasingly dominated by megadeals, masking continued difficulties for early-stage companies seeking capital.
What’s next: Isomorphic CEO Demis Hassabis said the new capital will help accelerate the company’s first therapeutic programs toward clinical trials. When we first highlighted Isomorphic earlier this year, the company was targeting its first patient dosing by the end of 2026. The latest announcement gives no updated timeline.




